<table>
<thead>
<tr>
<th>Title</th>
<th>Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Ishigooka, Nozomi</td>
</tr>
<tr>
<td>Citation</td>
<td>Kyoto University (京都大学)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2020-01-23</td>
</tr>
<tr>
<td>URL</td>
<td><a href="https://doi.org/10.14989/doctor.k22144">https://doi.org/10.14989/doctor.k22144</a></td>
</tr>
<tr>
<td>Type</td>
<td>Thesis or Dissertation</td>
</tr>
<tr>
<td>Textversion</td>
<td>ETD</td>
</tr>
</tbody>
</table>

Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis, Modern Rheumatology, 1439-7595(Print), 1439-7609(Online), https://doi.org/10.1080/14397595.2019.1621439
Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis

Nozomi Ishigooka, Takao Fujii, Hiroyasu Abe, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Hajime Yoshifuji, Masao Tanaka, Hiromu Ito, Koichiro Ohmura, Satoshi Morita & Tsuneyo Mimori

To cite this article: Nozomi Ishigooka, Takao Fujii, Hiroyasu Abe, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Hajime Yoshifuji, Masao Tanaka, Hiromu Ito, Koichiro Ohmura, Satoshi Morita & Tsuneyo Mimori (2019): Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis, Modern Rheumatology, DOI: 10.1080/14397595.2019.1621439

To link to this article: https://doi.org/10.1080/14397595.2019.1621439

View supplementary material

Accepted author version posted online: 22 May 2019.
Published online: 13 Jun 2019.

Submit your article to this journal

Article views: 106

View Crossmark data
Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis

Nozomi Ishigooka, Takao Fujii, Hiroyasu Abe, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Hajime Yoshifuji, Masao Tanaka, Hiromu Ito, Koichiro Ohmura, Satoshi Morita and Tsuneyo Mimori

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan; Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of the Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

ABSTRACT

Objectives: We aimed to determine the predicting factors for disappearance of anti-mutated citrullinated vimentin antibody (anti-MCV Ab) in sera from rheumatoid arthritis (RA) patients.

Methods: In 2013, 95 RA patients whose Disease Activity Score with erythrocyte sedimentation rate were moderate to severe (DAS28-ESR ≥ 3.2) at baseline were enrolled. Titers of anti-MCV Ab and anti-cyclic citrullinated peptide (anti-CCP) Ab for 2013 and 2014 were measured. The association of anti-MCV disappearance with disease activity, treatment, interstitial lung disease (ILD), and serum markers of ILD were retrospectively examined. Predicting factors of anti-MCV disappearance were determined by multivariable analysis.

Results: While anti-CCP positivity rate did not change during the year, anti-MCV Ab changed from positive to negative in 18 patients (19.0%). Continuous biological disease-modifying anti-rheumatic drug use, prednisolone dose (≥ 5.0 mg daily), and low KL-6 level (< 191 U/mL) were determined as predicting factors of anti-MCV disappearance by multivariable analysis. In our cohort, anti-MCV Ab disappearance was not linked to clinical and radiological improvement.

Conclusion: Different from anti-CCP Ab, anti-MCV Ab in sera from RA patients can disappear in a year. Some predicting factors for such negative seroconversion were found, whereas clinical significance of anti-MCV Ab disappearance was undetermined.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease that injures cartilage and bone by chronic inflammation. Since anti-citrullinated protein/peptide antibodies (ACPAs) are specifically observed in RA [1,2], anti-cyclic citrullinated peptide antibody (anti-CCP Ab) is clinically important for diagnosing RA [3]. Additionally, anti-CCP-positive RA patients showed more radiographic progressions than anti-CCP-negative patients [4,5]. Citrullinated vimentin, fibrinogen, type II collagen, and α-1-enolase are well-known target antigens of ACPA [6]. The association of an individual Ab against each citrullinated autoantigen with the pathogenesis of RA has recently been studied. Mutated citrullinated vimentin (MCV), an isoform of citrullinated vimentin, in which glycine residues are replaced by arginine, was found in synovial fluid of RA patients, and ELISA for anti-MCV Ab was developed by Bang et al. [7]. While both anti-MCV and anti-CCP Abs are specific for RA [8], the anti-MCV titer may be more correlated with disease activity and radiographic progression than the anti-CCP titer [9,10]. Recently, anti-MCV Ab was reported to react with osteoclasts and lead to bone loss [11]. In early RA patients treated with initial therapy, anti-(non-mutated) citrullinated vimentin Ab was the most frequent to disappear among anti-CCP, anti-citrullinated fibrinogen, and anti-citrullinated α-1-enolase Ab. Moreover, anti-MCV Ab disappearance was correlated with better radiographic outcome [12]. Several studies have reported that ACPA positivity is closely associated with interstitial lung disease (ILD) in RA [13,14]. Moreover, citrullinated proteins are observed in lung tissues with RA-ILD [15]; hence, ACPA genesis in focal organ has been discussed recently. Krebs von de Lungen-6 (KL-6) [16–18] and surfactant protein D (SP-D) [19] were both reported as serum markers of ILD including RA-ILD and demonstrated that its serum levels could be useful for detecting ILD and evaluating ILD activity.

It is believed that immunological remission, which is the seroconversion from positive to negative for autoantibodies (auto-Abs) and is a deeper remission than clinical or imaging remission, may be required for drug-free remission [20]. However, it is rare that anti-CCP Ab titer is decreased to negative range in clinical practice. The purpose of the

CONTACT Takao Fujii takfujii@wakayama-med.ac.jp Department of Rheumatology and Clinical Immunology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan

Supplemental data for this article can be accessed here.
The present study is to examine the frequency, clinical significance, and predicting factors of negative seroconversion of anti-MCV Ab, which is known to be more pathogenic [11] and be more changeable than anti-CCP Ab [12].

Methods

Patients
From 2013 to 2014, 280 RA patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria in Kyoto University RA Management Alliance (KURAMA) cohort. Actually, many patients achieved sustained clinical remission and low disease activity in both 2013 and 2014. In such patients, no major modification of DMARD treatment was observed because treatment target is already achieved. It would be impossible for such patients to examine clinical significance of anti-MCV Ab. Inclusion criteria in this retrospective study, therefore, is to have moderate or high Disease Activity Score-28 (DAS-28) activity with erythrocyte sedimentation rate (ESR) (DAS28-ESR $\geq 3.2$) in 2013. Because patients who newly started ($n=5$), stopped ($n=2$), and switched ($n=2$) biological disease-modifying antirheumatic drugs (bDMARDs) during the year were excluded for accurate treatment analysis, 95 patients were enrolled in the present study.

The study was designed in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (approval number: E458). Before enrollment, written informed consent was obtained from all patients.

ACPA measurement
ELISA kit was used for anti-MCV (Orgentec Diagnostika, Mainz, Germany) and anti-CCP (Medical & Biological Laboratories Co., Nagoya, Japan). According to the manufacturers’ instructions, positive values were set to $\geq 20$ U/mL for anti-MCV and $\geq 4.5$ U/mL for anti-CCP, respectively.

Assessment of ILD
We examined ILD, including serum markers in this study. From chest CT scans, each attending rheumatologist and radiologist determined whether an enrolled patient had ILD. In 2013, KL-6 and SP-D were both measured at baseline. KL-6 was measured by electrochemiluminescence immunoassay (Sekisui Medical Corp., Tokyo, Japan) and SP-D by ELISA (Yamasa Shoyu Corp., Choshi, Japan).

Radiographic evaluation of arthritis
Eighty-four patients were available for scoring radiographs of hands and feet during both years. All radiographs were dually evaluated by two readers and scored using the van der Heijde modified Total Sharp Score (mTSS), which is based on the sum of joint erosion score ($\Delta$JES) and joint space narrowing (JSN). Each average of the progression score ($\Delta$mTSS) during a year was used for analysis.

Statistical analysis
Univariate analysis was performed using Fisher’s exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Logistic regression analysis was used for multivariate analysis. Multivariable analysis was performed using variables with $p < .05$ in the univariate analysis. ILD existence is correlated with both KL-6 and SP-D. Thereafter, multivariate logistic regression analysis was performed separately in three models, which included three correlated variables one by one. Since none of the patients had ILD in the anti-MCV disappearance group, we used Firth’s method for ILD variables [21]. To compare anti-MCV disappearance rate in the bDMARD use group with that in the non-use group and in ILD group with that in the non-ILD group, Fisher’s exact test was used. The receiver operating characteristic (ROC) curves were conducted to determine the cutoff level of the serum marker of ILD and the prednisolone (PSL) dose for anti-MCV disappearance. The Spearman correlation coefficient was used to determine the correlation of anti-MCV and anti-CCP titers. All analyses were performed using JMP Pro version 12 (SAS Institute Inc., Cary, NC).

Results

Characteristics of the enrolled patients
The profiles and treatments for 95 patients in 2013 and 2014 are shown in Table 1. The mean age was 64.9 years and disease duration was 16.3 years in 2013. The mean of

<table>
<thead>
<tr>
<th>Table 1. Profiles of enrolled RA patients.</th>
<th>2013</th>
<th>2014</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.9 ± 11.0</td>
<td>65.9 ± 11.2</td>
<td>–</td>
</tr>
<tr>
<td>Female (%)</td>
<td>85.2</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>16.3 ± 12.3</td>
<td>17.3 ± 12.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>21.8</td>
<td>15.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>DAS28 (ESR)</td>
<td>4.23 ± 0.87</td>
<td>3.59 ± 1.01</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.07 ± 0.71</td>
<td>1.06 ± 0.79</td>
<td>–</td>
</tr>
<tr>
<td>$\Delta$mTSS (2014–2013)</td>
<td>–</td>
<td>1.00 ± 2.34</td>
<td>n.s.</td>
</tr>
<tr>
<td>$\Delta$JES</td>
<td>–</td>
<td>0.39 ± 1.22</td>
<td>n.s.</td>
</tr>
<tr>
<td>$\Delta$JSN</td>
<td>–</td>
<td>0.60 ± 1.39</td>
<td>n.s.</td>
</tr>
<tr>
<td>ILD (%)</td>
<td>16.8</td>
<td>16.8</td>
<td>–</td>
</tr>
<tr>
<td>PSL user (%)</td>
<td>47.3</td>
<td>44.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Dose* (mg/day)</td>
<td>2.4 ± 3.3</td>
<td>2.5 ± 3.6</td>
<td>n.s.</td>
</tr>
<tr>
<td>csDMARD user (%)</td>
<td>64.2</td>
<td>64.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>MTX user (%)</td>
<td>69.4</td>
<td>67.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Dose* (mg/week)</td>
<td>5.0 ± 4.2</td>
<td>4.4 ± 3.9</td>
<td>n.s.</td>
</tr>
<tr>
<td>bDMARD user (%)</td>
<td>35.8</td>
<td>35.8</td>
<td>–</td>
</tr>
<tr>
<td>TNF inhibitor (%)</td>
<td>24.2</td>
<td>24.2</td>
<td>–</td>
</tr>
<tr>
<td>Tocilizumab (%)</td>
<td>6.3</td>
<td>6.3</td>
<td>–</td>
</tr>
<tr>
<td>Abatacept (%)</td>
<td>5.3</td>
<td>5.3</td>
<td>–</td>
</tr>
</tbody>
</table>

*Average of dose is calculated, including patients who do not take PSL or MTX. bDMARD: biological disease-modifying antirheumatic drug; CCP: cyclic citrullinated peptide; csDMARD: conventional synthetic disease-modifying anti-rheumatic disease; DAS: disease activity score; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; ILD: interstitial lung disease; JES: joint erosion score; JSN: joint space narrowing; MCV: mutated citrullinated vimentin; mTSS: van der Heijde modified total sharp score; MTX: methotrexate; PSL: prednisolone; n.s.: not significant.
DAS28-ESR decreased from 4.23 to 3.59 during a year, whereas the health assessment questionnaire (HAQ) remained almost unchanged. Radiographic change evaluated by DmTSS was 1.00, change in joint erosion score (ΔJES) was 0.39, and change in joint space narrowing (ΔJSN) was 0.60. In 2013, methotrexate (MTX), PSL use, and bDMARD use was 69.4%, 47.3%, and 35.8%, respectively. Although mean DAS28 at 2014 was 3.59 in the present cohort, 64.8% of the enrolled patients had SDAI remission or low disease activity in 2014 and 47.1% of patients had EULAR good or moderate response.

**Correlation between anti-MCV and anti-CCP titers**

In the 2013 cohort, anti-MCV and anti-CCP positivity rates were 71.5% (n = 68) and 89.5% (n = 85), respectively (Table 2). Most (97.0%) of anti-MCV-positive patients had anti-CCP Ab, and there was significant correlation between anti-MCV and anti-CCP titers (r = 0.67, p < .001). In contrast, there was no correlation between the change in anti-MCV titer and anti-CCP during a year (r = 0.20, p = .04) (Figure 1). There were no differences in patients’ profile and treatment between anti-MCV positive and negative groups in 2013 (Supplementary Table 1).

**Table 2. Change in ACPA in each year.**

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-CCP positive (%)</td>
<td>89.5</td>
<td>89.5</td>
<td>n.s.</td>
</tr>
<tr>
<td>Anti-MCV positive (%)</td>
<td>71.5</td>
<td>61.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Remained positive</td>
<td>–</td>
<td>52.6</td>
<td>–</td>
</tr>
<tr>
<td>Remained negative</td>
<td>–</td>
<td>20.0</td>
<td>–</td>
</tr>
<tr>
<td>Changed from negative to</td>
<td>–</td>
<td>8.4</td>
<td>–</td>
</tr>
<tr>
<td>positive (appeared)</td>
<td>–</td>
<td>19.0</td>
<td>–</td>
</tr>
<tr>
<td>Changed from positive to</td>
<td>–</td>
<td>363 ± 398</td>
<td>n.s.</td>
</tr>
<tr>
<td>negative (disappeared)</td>
<td>–</td>
<td>215 ± 398</td>
<td>–</td>
</tr>
<tr>
<td>Anti-CCP titer (U/mL)</td>
<td>718 ± 1772</td>
<td>382 ± 833</td>
<td>n.s.</td>
</tr>
<tr>
<td>Anti-MCV titer (U/mL)</td>
<td>215 ± 398</td>
<td>363 ± 398</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

(n = 95).

CCP: cyclic citrullinated peptide; MCV: mutated citrullinated vimentin; n.s.: not significant.

**Change in anti-MCV positive rates between 2013 and 2014**

While the anti-CCP positivity rate did not change (89.5%) from 2013 to 2014, the anti-MCV positivity rate changed from 71.5% to 61.0% (Table 2). Specifically, anti-MCV titers changed from positive to negative in 19.0% of the patients (disappeared group) and from negative to positive in 8.4% (appeared group). The 2014 titers remained positive in 52.6% of the patients (remained positive group) and 20% were still negative (remained negative group).

**Comparison between the profiles of the anti-MCV remained positive and disappeared groups**

To explore the predicting factor for anti-MCV disappearance, we compared the anti-MCV remained positive and disappeared groups by univariate analysis (Table 3). Age and disease duration were similar in both groups, while female patients tended to be frequent in the disappeared group than in the remained positive group (100.0% vs. 80.0%, p = .052). While there were no differences in DAS28 and HAQ in 2013 baseline between both groups, ΔHAQ from 2013 to 2014 in the disappeared group was more apparent than that in the remained positive group (–0.18 vs. 0.035, p = .038). Between the remained positive and disappeared groups, no difference was seen in ΔmTSS (1.43 vs. 1.03, p = .43), ΔJES (0.57 vs. 0.27, p = .86), and ΔJSN (0.85 vs. 0.75, p = .77) (Supplementary Figure 1).

At baseline, there was no correlation between anti-MCV Ab titer and DAS28 (r = 0.17). Also, correlation between Δanti-MCV and ΔDAS was not found (r = 0.08) (Supplementary Figure 2). Little correlation between Δanti-MCV Ab titer and ΔHAQ (r = 0.26, p = .01) was observed (Data not shown).

There were no ILD patients in the disappeared group, while 22.0% of patients had ILD in the remained positive group (p = .029). Additionally, KL-6 and SP-D [14–19] were lower in the disappeared group than in the remained positive group at baseline (KL-6 191 vs. 314 U/mL, p = .0004;
SP-D 40.1 vs. 67.0 ng/mL, p = .02) in 2013. While there was no difference in PSL users between both groups, the PSL dose in the disappeared group was higher than that in the remained positive group (30.7 vs. 20.6, n.s.). There were no differences in MTX monotherapy and dosage of MTX between both groups. bDMARD were more frequently used longer in the disappeared group than in the remained positive group (72.2% vs. 30.0%, p = .0043; 1.77 ± 2.55 vs. 0.66 ± 1.61 years, p = .0063). Also, there was no difference of bMDARD use between in patients with ILD and without ILD (45.4% vs. 40.3%, p = .75) in our cohort.

**Multivariate analysis of the predicting factors for anti-MCV disappearance**

A multivariate analysis was performed to identify the predicting factors for anti-MCV disappearance. We selected anti-MCV titer in base line, ΔHAQ, PSL dose, bDMARD use, ILD complications, and serum markers of ILD, which appeared to be the predicting factors (p < .05) in the univariate analysis. Since ILD (model A) and serum markers of ILD (model B: SP-D and C: KL-6) were correlated, the multivariable analysis was performed separately in three models (Table 4). All models indicated that bDMARD use (model A: OR: 5.35, p = .01; model B: OR 4.65, p = .027; model C: OR 5.95, p = .01) and PSL dose (≥5.0 mg daily) (model A: OR 1.22, p = .04; model B: OR 1.24, p = .027; model C: OR 1.25, p = .02) were the predicting factors for anti-MCV disappearance. While there was no relation between ILD and anti-MCV disappearance in model A (OR 0.11, p = .14) and between SP-D and anti-MCV disappearance in model C (OR 0.84, p = .11), lower levels of KL-6 were associated with anti-MCV disappearance in model B (OR 0.51, p = .043).

**Association between anti-MCV disappearance and bDMARD use**

Since the multivariable analysis indicated bDMARD use as an independent predicting factor for anti-MCV disappearance.
disappearance, we examined anti-MCV disappearance rate in bDMARD users (continuous use between 2013 and 2014) and non-users (Figure 2). Anti-MCV disappearance was more frequently observed in bDMARD users than in non-users (42.3% vs. 10.2%, \( p = .005 \)). Also, decrease of anti-MCV Ab titer was significant in bDMARD users than in non-users (\(-493 \pm 1727 \) vs. \(-247 \pm 1785 \) U/mL, \( p = .005 \)).

**Association between anti-MCV disappearance and ILD or serum marker of ILD**

To consider the possible association between ILD and anti-MCV disappearance, we examined the anti-MCV disappearance rate in ILD and non-ILD patients (Figure 2). While anti-MCV disappearance was not recognized in ILD patients, the disappearance rate was 30.5% in non-ILD patients \( (p = .02) \). The decreased titer of anti-MCV Ab was not statistically different between in ILD and non-ILD patients \((-186 \pm 1296 \) vs. \(-1075 \pm 3156 \) U/mL, \( p = .94 \)).

**Association between anti-MCV disappearance and PSL dose**

To examine the amount of PSL that affects anti-MCV disappearance, the cutoff value was estimated by ROC analysis (Figure 3(b)). The cutoff PSL dose was 5.0 mg with 55.5% sensitivity, 84.0% specificity, and 0.65 AUC. Additionally, the anti-MCV disappearance rate was higher in patients with high PSL dose \( (\geq 5.0 \text{ mg daily}) \) than in patients with low PSL dose \( (< 5 \text{ mg daily}) \) (55.8% vs. 16.0%, \( p = .0017 \)).

**Predicting factor of anti-MCV appearance**

Comparing the anti-MCV appeared group \( (n = 8) \) with the remained negative group \( (n = 19) \), no differences were recognized in their background profiles, disease activity, and treatments (Supplementary Table 2). Therefore, the predicting factor for anti-MCV development was not determined.

**Discussion**

Since anti-CCP disappearance is rare, there are very few reports regarding anti-CCP disappearance [22]. In contrast, anti-Sa Ab, which is identical to anti-citrullinated vimentin Ab, was previously reported to frequently disappear [23]. This is the first report to determine factors predicting anti-MCV disappearance.

Kastbom et al. reported that anti-(non-mutated) citrullinated vimentin Ab may most frequently disappear among
ACPAs, including anti-CCP, anti-citrullinated fibrinogen, and α-enolase Abs, after intensive RA treatment in the Swedish Farmacotherapy (SWEFOT) trial [12]. In addition, anti-(non-mutated) citrullinated vimentin Ab is statistically associated with better radiographic outcome [12]. In our cohort, however, there appeared to be no correlations of anti-MCV titers with disease activity and radiographic progression. These results suggested that anti-MCV titer is not always associated with RA disease activity change in our cohort. This discrepancy may be caused by the difference in the observation period as the radiographic evaluation in the SWEFOT trial was performed for 2 years, which is longer than our study (1 year). The enrolled patients were also different; the majority of the SWEFOT trial included early RA patients, while our study included established patients. Additionally, non-mutated citrullinated vimentin was used in the SWEFOT trial, but ‘mutated’ citrullinated vimentin is used in our study. Serum Abs in RA patients react more actively with ‘mutated citrullinated vimentin’ than with non-mutated citrullinated vimentin [7].

Infliximab [24] and rituximab [25] are bDMARDs which reportedly decrease the Ab titers against citrullinated vimentin. Similarly, our data indicated that negative seroconversion of anti-MCV Ab can occur with bDMARD treatment. It should be interesting to determine the mode of action that favors anti-MCV disappearance. However, the number of patients using bDMARD in our cohort was too few to answer this important point. Previously, anti-CCP titers were reported to be decreased by rituximab [25], abatacept [26], and tumor necrosis factor (TNF) inhibitors [26]. In addition to rituximab which affects B cells, abatacept is reported to suppress B cells through IL-17 inhibition [27], and TNF inhibitors are also reported to decrease memory B cells [25,28,29] in RA. These mechanisms of B cell downregulation by bDMARD might lead to anti-MCV disappearance. On the other hand, bDMARD treatment can suppress citrulline-reactive Th1 cells in patients with RA [30]. It is possible that bDMARD treatment decreases MCV-reactive T cells by bDMARD use. Whereas it is required to determine the detailed mechanism of bDMARD-mediated anti-MCV Ab disappearance, the sustained use of bDMARD may be preferable for negative seroconversion of anti-MCV Ab.

Harre et al. reported that MCV antigen can be expressed on osteoclast precursors and recognized by anti-MCV Ab [11]. Since bDMARDs can suppress osteoclast formation regardless of their mode of action, MCV antigen on osteoclasts may be downregulated. As the appearance of high titers of ACPA production is antigen-driven [31,32] and T cell-dependent [33–35], another possible mechanism of anti-MCV disappearance in bDMARD users can be attributed to decreased autoantigens.

Our data suggested possible correlation between ILD and anti-MCV disappearance, whereas sustained bDMARD use might be more dominant factor than ILD. The generation of anti-CCP Ab is closely associated with RA-ILD [14]. ACPAs have been detected in sputum from seronegative patients at risk of RA due to family history [36]. In another previous study, ACPA levels were higher in bronchoalveolar lavage fluid than in serum from ACPA-positive RA patients [37]. These reports suggest that ACPA production may be stimulated by pulmonary tissue modification followed by active vimentin citrullination. Considering these data together with our results, continuous activation of vimentin citrullination might stimulate anti-MCV Ab production. In association with ILD, note that low KL-6 level (<191 IU/mL) was recognized as the predicting factor for anti-MCV disappearance. Whereas SP-D is a useful marker in RA-ILD, as well as KL-6 [14], SP-D appeared not to be associated with anti-MCV disappearance in our cohort. Both markers are derived from alveolar epithelial type II cells (AECIIs). Although KL-6 is expressed in all phases of AECIIs, SP-D is expressed only in matured AECIIs [38–40]. Our data suggested that the immature phase of AECIIs may also be important for MCV expression.

The PSL dose (≥5.0 mg daily), but not PSL use, was one of the predicting factors for anti-MCV disappearance in multivariate analysis. Since PSL is the most effective agent for extra-articular manifestation, vimentin citrullination in other tissues, apart from lungs, may be suppressed by daily dosage of PSL at 5 mg or higher.

In conclusion, we strongly suggest that bDMARD use, ≥5.0 mg daily dose of PSL, and low KL-6 level are the independent predicting factors for anti-MCV disappearance. Additionally, anti-MCV disappearance occurs particularly in RA patients without ILD. There are, however, some limitations in the present study. Our data is retrospective observation of small number of patients in a single center. Also, most patients had established RA. To determine clinical significance of anti-MCV disappearance in RA patients, a prospective study using larger size of patient cohort should be conducted.

Acknowledgments

We would like to thank Akiko Yoshida for scoring mTSS.

Conflict of interest

KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd. This study is conducted as investigator-initiated study. These companies had no role in the design of the study, collection, or analysis of data, the writing of the manuscript or decision to submit the manuscript for the publication. T.F. has received a research grant and/or speaker fee from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi-Tanabe Pharma Corporation, Eisai Co., Ltd., AbbVie GK, and Astellas Pharma Inc. M.H. and M.T. belong to a department that is financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI, and UCB Japan). M.T. received scholarship donations from six pharmaceutical companies (Pfizer, Astellas, AbbVie GK, Taisyo Toyama, Takeda, and Eisai). M.H. received a grant from Astellas Pharma Inc., Bristol-Myers Squibb, and ONO Pharma. HI received research grant from BMS, Astellas, and Asahi-Kasei. S Morita received honoraria from four pharmaceutical companies (Pfizer, Bristol-Myers Company, ONO Pharma, Chugai). T Mimori has received research grants from Astellas, Asahi Kasei Pharma, Ayumi, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Mitsubishi-Tanabe, Nippon Kayaku, Nippon Shinyaku, Pfizer, Sanofi, and Takeda and speakers’ fee from Bristol-Myers Squibb, Chugai, and Mitsubishi-Tanabe.
References


33. van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de Stadt RJ, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with


